JD Health announced its financial results for the first quarter of 2026. For the three months ended March 31, 2026, the Group achieved revenue of RMB 194.68 billion, representing a year-on-year increase of 17%. Operating profit reached RMB 18.25 billion, marking a significant growth of 70.4% compared to the same period last year.

During Q1 2026, JD Health established strategic partnerships with several leading pharmaceutical companies, including Organon, Kenvue, CR Jiangzhong, and Shou'er Pharmaceutical. Notably, the collaboration with Organon focuses on advancing the practical application of AI-assisted diagnosis and treatment, as well as digital disease management, in areas such as cardiovascular, respiratory, and women's health.

Concurrently, JD Health continued to reinforce its core advantage as the "primary launch platform for new drugs online." The company launched over 30 new drugs in the first quarter. These included Remibrutinib®, developed by Novartis, which is the world's first approved oral targeted therapy for Chronic Spontaneous Urticaria, and Balutozumab®, the first innovative drug approved in China for the treatment of Vitiligo.

In the first quarter of 2026, JD Health's AI medical service, "AI Jingyi," was deeply integrated to form a closed-loop service encompassing "medical consultation, testing, diagnosis, and medication." For user health inquiries, the service not only provides professional advice but also directly facilitates online consultations, at-home rapid testing, nurse home visits, and medication fulfillment through JD Pharmacy, creating a comprehensive service cycle.

The number of users utilizing the AI doctor "Da Wei" in the first three months of 2026 has already surpassed the total user count for the entire year of 2025.